Replies to post #438008 on Amarin Corp Plc (AMRN)

[Whalatane]

RMB. While this trial doesn't test Vazkepa in isolation it may lead to more immediate use of Vazkepa following a CV event , assuming the event curves diverge and are stat sig etc )
If the trial succeeds than there will be more immediate use of Vazkepa per R-IT guidelines in acute patients ...and AMRN will use this to expand use in other EU health depts

By the way ...REDUCE-IT wasn't only about patients with Acute coronary syndrome ...but they found a lot of benefit for those prescribed Vascepa within 12 mths of a CV event

. A post-hoc analysis specifically found that in patients who had experienced ACS less than 12 months prior to randomization, IPE significantly reduced the risk of first and total ischemic events by 37% and 36%, respectively, without increasing bleeding, supporting the early initiation of IPE after ACS.

So if this is repeated ( or close to it ) in the GOLDEN trial ...huge for AMRM
JMO
Kiwi